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The most common sites of breast cancer metastasis are the bone, lung, liver and brain. However, colonic
metastases from breast cancer are very rare in the clinic. We describe an unusual case of sigmoid colonic
metastasis from invasive ductal breast cancer. With this report, we should increase the clinical awareness that any
patient with a colorectal lesion and a history of malignancy should be considered to have a metastasis until
proven otherwise. Early diagnosis is very important, which enables prompt initiation of systemic treatment, such
as chemotherapy, endocrine therapy or both, thus avoiding unnecessary radical surgical resection and improving
the prognosis.
Keywords: Breast cancer, Sigmoid colon, Metastasis, Invasive ductal cancerBackground
Metastatic involvement of the gastrointestinal tract sec-
ondary to breast cancer is rare [1] and sigmoid colonic
metastasis from breast cancer is even rarer. Metastatic
breast carcinoma involvement of the gastrointestinal
tract is usually of the lobular histologic subtype [2]. To
the best of our knowledge, the case presented here is
one very rarely reported in literature, showing sigmoid
colonic metastasis from invasive ductal breast cancer.
Case presentation
A 54-year-old woman was admitted to our hospital with
pain in the left lower abdomen in April 2011. She had
undergone modified radical mastectomy for an invasive
ductal carcinoma of the right breast in December 2002.
Histopathological examination revealed a 3.0 × 3.0 cm
invasive ductal carcinoma of histological grade 3 and all
seven resected axillary lymph nodes were negative
for carcinoma. Immunohistochemistry (IHC) staining
showed that the right breast cancer was positive for es-
trogen receptor (ER), progesterone receptor (PR) and
p53, but negative for human epidermal growth factor
receptor-2 (HER-2). The patient received adjuvant* Correspondence: bobzxccc@163.com; zxc100952@163.com
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During a period of six years and one month, she was free
of disease until January 2009, when she developed left
breast carcinoma, for which she had undergone modified
radical mastectomy. Histopathological examination
revealed a 3.5 × 2.5 cm invasive ductal carcinoma of
histological grade 3 and two of seventeen axillary lymph
nodes were positive for carcinoma. IHC staining showed
that the left breast cancer was positive for ER, PR and
p53, but negative for HER-2. The patient received adju-
vant chemotherapy, radiotherapy and endocrine therapy
postoperatively. She had also undergone a total hysterec-
tomy and bilateral salpingo-oophorectomy for left ovar-
ian metastasis of breast carcinoma in November 2010,
followed by second-line chemotherapy.
Physical examination revealed no palpable abdominal
mass. Laboratory results showed mild anemia (hemoglobin
level, 105 g/L), serum carbohydrate antigen (CA)125 level
elevated to 134.4 kU/L (normal, 0 to about 35.0 kU/L), and
serum CA724 level elevated to 139.8 kU/L (normal, 0 to
about 6.9 kU/L), while serum levels of CA199, CA153, and
carcinoembryonic antigen (CEA) were within the normal
range. Endoscopy of the sigmoid showed mucosal irregular
hyperplasia at 16 to about 30 cm above the anal verge, tak-
ing up about half of the intestinal lumen. The affected mu-
cosal surface was eroded, necrotic, friable and prone to
bleeding (Figure 1). Contrast-enhanced computed tomog-
raphy (CT) showed eccentric wall thickening of the distaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 3 The sigmoid colonic biopsy specimen showed
histological features of poorly differentiated adenocarcinoma
which was quite similar to that of the previous invasive
ductal breast cancer (hematoxylin&eosin stain; original
magnification × 200).
Figure 1 Endoscopy of the sigmoid showed mucosal irregular
hyperplasia at 16 to about 30 cm above the anal verge, taking
up about half of the intestinal lumen. The affected mucosal
surface was eroded, necrotic, friable and prone to bleeding.
Figure 4 Invasive ductal carcinoma in the right breast
(hematoxylin&eosin stain; original magnification × 400).
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density mass causing an apparent stenosis and nodular low
density shadow in the left side (Figure 2). The sigmoid
colonic biopsy specimen showed histological features of
poorly differentiated adenocarcinoma (Figure 3) which
was quite similar to that of the previous invasive ductal
breast cancer (Figures 4 and 5). IHC staining (Figure 6)
showed that the sigmoid colon cancer was negative forFigure 2 Contrast-enhanced CT showed eccentric wall
thickening of the distal sigmoid colon with a significantly
enhanced soft tissue density mass causing an apparent
stenosis (arrow) and nodular low density shadow in the left
side. CT, computed tomography.
Figure 5 Invasive ductal carcinoma in the left breast
(hematoxylin&eosin stain; original magnification × 200).
Figure 6 Immunohistochemistry staining showed that the sigmoid colon cancer was positive for cytokeratin 7 (CK7) (original
magnification × 100) (A). Immunohistochemistry staining showed that the sigmoid colon cancer was negative for cytokeratin 20 (CK20)(original
magnification × 100) (B). Immunohistochemistry staining showed that the sigmoid colon cancer was negative for cauda-related homeobox
transcription factor 2 (CDX2)(original magnification × 100) (C). Immunohistochemistry staining showed that the sigmoid colon cancer was
negative for Villin(original magnification × 100) (D). Immunohistochemistry staining showed that the sigmoid colon cancer was negative for
thyroid transcription factor-1 (TTF-1) (original magnification × 100) (E). Immunohistochemistry staining showed that the sigmoid colon cancer was
negative for human epidermal growth factor receptor-2 (HER-2)(original magnification × 100) (F). Immunohistochemistry staining showed that
the sigmoid colon cancer was negative for estrogen receptor (ER)(original magnification × 100) (G). Immunohistochemistry staining showed that
the sigmoid colon cancer was negative for progesterone receptor (PR)(original magnification × 100) (H).
Table 1 Immunohistochemical markers for the primary bilateral invasive ductal breast cancer and metastases
The right breast cancer The left breast cancer The left ovarian metastasis The sigmoid colonic metastasis
ER 15% estrogen receptor positive 20% estrogen receptor positive 20% estrogen receptor weak
positive
0 estrogen receptor positive






0 progesterone receptor positive
HER-2 negative negative negative negative
p53 positive positive positive positive
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Villin, thyroid transcription factor-1 (TTF-1), cytokeratin
(CK)20, HER-2, ER and PR, but positive for CK7 and
p53. IHC staining also showed that the positive cell popu-
lation of Ki-67 was 30%. The sigmoid colonic lesion was,
therefore, diagnosed to be a metastasis from the original
breast cancer.
Conclusions
The diagnosis was invasive ductal breast cancer meta-
static to the sigmoid colon, which as a clinical entity can
be easily misdiagnosed as primary sigmoid colon cancer.
In the presented material, besides the medical history, a
firm diagnosis of metastatic breast carcinoma to the sig-
moid colon could be established fundamentally. It was
based on the histology of the endoscopic biopsy speci-
men and immunohistochemistry. Metastatic breast car-
cinomas are often positive for CK7, ER and PR, but
negative for CK20 and CDX2[2]. CK7 was positive but
CK20 and CDX2 were negative in the present case,
which was similar to reports in the literature. However,
ER and PR were negative in the sigmoid colon site,
which was different from a positive expression of the pri-
mary bilateral invasive ductal breast cancer (Table 1).
The conversion from hormone receptor positive in the
primary tumor to hormone receptor negative in the me-
tastasis has also been reported in a series of studies [3,4].
The diagnosis of colorectal metastasis is difficult not
only because it is infrequent but also because of its non-
specific clinical presentation and variable radiographic
features [5]. So clinicians should increase their clinical
awareness that any patient with a colorectal lesion and a
history of malignancy should be considered to have a
metastasis until proven otherwise. The therapeutic man-
agement of colorectal metastasis is still controversial.
Surgical resection should be reserved for palliation of in-
testinal obstruction or bleeding [6]. Many authors
underline the importance of early diagnosis, which
enables prompt initiation of systemic treatment, such as
chemotherapy, endocrine therapy or both, thus avoiding
unnecessary radical surgical resection and improving the
prognosis. Our patient underwent second-line chemo-
therapy and endocrine therapy after the diagnosis of sig-
moid colonic metastasis from breast cancer. She is alive
with disease and in stable condition at present.
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